Similar articles

• Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.

  Ferdinand KC. Ferdinand KC. Expert Opin Pharmacother. 2005 Sep;6(11):1897-910. doi: 10.1517/14656566.6.11.1897. Expert Opin Pharmacother. 2005. PMID: 16144509 Review.
• Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

  Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P. Glueck CJ, et al. Clin Ther. 2006 Jun;28(6):933-42. doi: 10.1016/j.clinthera.2006.06.004. Clin Ther. 2006. PMID: 16860175 Clinical Trial.
• Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

  Hsia J, MacFadyen JG, Monyak J, Ridker PM. Hsia J, et al. J Am Coll Cardiol. 2011 Apr 19;57(16):1666-75. doi: 10.1016/j.jacc.2010.09.082. J Am Coll Cardiol. 2011. PMID: 21492764 Clinical Trial.
• Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.

  Wlodarczyk J, Sullivan D, Smith M. Wlodarczyk J, et al. Am J Cardiol. 2008 Dec 15;102(12):1654-62. doi: 10.1016/j.amjcard.2008.08.014. Epub 2008 Sep 20. Am J Cardiol. 2008. PMID: 19064019
• Clinical efficacy and safety of statins in managing cardiovascular risk.

  Kapur NK, Musunuru K. Kapur NK, et al. Vasc Health Risk Manag. 2008;4(2):341-53. doi: 10.2147/vhrm.s1653. Vasc Health Risk Manag. 2008. PMID: 18561510 Free PMC article. Review.